Skip to main content

Microfat & Nanofat Grafting (GSM / Vulvar Atrophy / Lichen Sclerosus)

Microfat and nanofat grafting is an autologous regenerative-medicine approach using mechanically processed adipose tissue to treat genitourinary syndrome of menopause (GSM), vulvovaginal atrophy, and vulvar dystrophies including lichen sclerosus (VLS). Microfat provides volume, and nanofat contains stromal cells and growth factors with hypothesized trophic effects. Small uncontrolled studies describe symptom and tissue-marker changes; the AUA/SUFU/AUGS 2025 guideline recommends offering low-dose vaginal estrogen for GSM .[1][2][3][18][40] For positioning versus other female cosmetic options see Cosmetic Genital Surgery — Female.

Therapeutic versus cosmetic context. Microfat or nanofat grafting for GSM, vulvovaginal atrophy, or lichen sclerosus refractory to topical steroids is a therapeutic indication with a small but maturing evidence base, distinct from purely cosmetic applications. ACOG 2020 Committee Opinion No. 795 classifies cosmetic genital procedures as not medically indicated, with safety and effectiveness not established; FIGO 2025 echoes this for cosmetic indications.[6] Counsel patients clearly on the therapeutic versus cosmetic distinction and document the indication.[4]

Safety. Severe pulmonary fat embolism was reported after combined vaginal and breast fat grafting; the authors considered vaginal injection the most likely source but could not establish it. Anatomical knowledge and careful injection technique remain important.[5]

Background — GSM and the limits of standard therapy​

GSM affects the majority of peri- and postmenopausal women and includes vaginal dryness, burning, itching, dyspareunia, urinary urgency, frequency, and recurrent UTIs, driven by estrogen deficiency and progressive vulvovaginal atrophy.[1][6] Standard treatments (topical estrogen, DHEA, ospemifene, moisturizers) are effective but require ongoing therapy to maintain benefit and cannot reverse the underlying atrophic process.[6][7] This limitation has driven interest in regenerative approaches that may provide longer-lasting tissue restoration.[7]

Definitions — macrofat vs microfat vs nanofat​

Fat typeParticle sizeHarvestingProcessingPrimary function
Macrofat> 2.4 mmStandard liposuction cannulaMinimalVolume restoration (large defects)[1][2]
Microfat< 1.2 mm parcels in one classification (method-dependent)Small multiport cannula (1–2 mm holes)Centrifugation or decantingVolume restoration with hypothesized trophic effects[1][2][3][8]
NanofatMicron-scale emulsion (size varies by method; no viable adipocytes in the original preparation)Derived from microfatMechanical emulsification + filtrationHypothesized trophic effects without reliable volumization[1][2][9]

Microfat uses a multiport cannula with small (0.8–1 mm) side holes, retaining intact adipocytes and providing both volume and regenerative capacity.[8][9]

Nanofat was first described by Tonnard et al. 2013 and is produced by mechanical emulsification (vigorous back-and-forth between two syringes via a Luer-lock connector, typically 30 passes) followed by filtration through a nylon mesh. The process destroys all viable adipocytes but preserves abundant adipose-derived stem cells (ADSCs), stromal vascular fraction (SVF) cells, growth factors, and extracellular matrix components. The resulting fluid emulsion can be delivered through fine needles (up to 27-gauge).[9]

Biological rationale and mechanism​

The therapeutic effects extend beyond simple volume replacement:

  • ADSCs. Nanofat contains abundant ADSCs with proliferation and differentiation capacity equivalent to unprocessed fat; multilineage differentiation (adipocyte, osteocyte and chondrocyte) plus highly pluripotent MUSE cells.[9][10]
  • Proteomic profile. Mechanical emulsification of microfat into nanofat upregulates pathways involved in innate immunity, coagulation, wound healing, and antimicrobial defense.[11]
  • Lipidomic profile. Nanofat is enriched in anti-inflammatory, antifibrotic, and antimelanogenic lipid mediators (prostacyclin, coumaric acids) versus microfat.[12]

Histologic observations in very small samples (one separate Lai 2023 patient and three Casarotti 2018 patients):[13][3]

  • Neocollagenesis: increased collagen production
  • Neoangiogenesis: new blood-vessel formation
  • Increased estrogen-receptor expression: enhanced local hormonal responsiveness
  • Decreased PGP 9.5 (neuropathic-pain marker)
  • Glycogen production, epithelial regeneration, and restoration of lactobacilli colonization with normalization of vaginal pH (sustained at 36 mo)

Surgical technique​

1. Fat harvesting​

  • Donor sites: abdomen, medial thighs, flanks. No significant difference in fat-cell viability between sites.[1][14]
  • Multiport cannula with small side holes for microfat.[1][14]
  • Local or general anesthesia.

2. Fat processing​

StepDetail
MicrofatCentrifugation typically 3 min at 3,000 rpm, or decanting, to separate fat from aqueous and oil fractions.[14][8]
NanofatMicrofat is mechanically emulsified by passing between two syringes (~ 30 times) and then filtered through nylon mesh. The result is a homogeneous, fluid emulsion.[9]
PRP enrichmentFat-graft processing methods vary.[14] A vulvar lichen sclerosus pilot combined nanofat with PRP but compared the combination with topical clobetasol, leaving PRP's added benefit untested.[15] A separate genital lichen sclerosus study compared SVF with and without PRP, rather than nanofat with and without PRP.[20]

3. Injection​

Menkes 2021 protocol (the landmark vulvovaginal series):[1]

  • Microfat to labia majora (volume restoration of atrophic or deflated labia majora).
  • Nanofat to vaginal mucosa (submucosal) (tissue regeneration).

Lai 2023 MAFT used an 18G blunt cannula to place small fat parcels into posterior vaginal submucosa (3-to-9-o'clock arc); a rectal finger checked cannula depth to avoid perforation. Mean injected volumes were 21.9 mL vaginally and 20.8 mL in the vulva and mons.[13]

Anesthesia varies by protocol: Lai's MAFT series used intravenous anesthesia, whereas the Lichen-SVF series used local anesthesia with light sedation.[13][19]

Clinical evidence​

GSM / vulvovaginal atrophy​

StudynTechniqueFollow-upKey outcomes
Menkes 2021[1]50Microfat (labia) + nanofat (vagina)18 moVHI + FSD significantly improved (p < 0.0001); 80% normalized at 6 mo; stable at 18 mo; particular benefit for dryness and dyspareunia
Casarotti & Tremolada 2020[16]35MFAT (vulvar injection)36 moUncontrolled series: 30/35 (85%) asymptomatic at 12 mo; 3/35 reported mild symptoms at 24–36 mo. One scar-related nonresponder received a second injection at 14 mo.
Casarotti 2018[3]3MFAT (Lipogems®)36 moMarked symptom improvement by 9 mo, with mild residual symptoms in some women; histology — glycogen production, vascular hyperplasia, epithelial regeneration, lactobacilli restoration
Lai 2023 MAFT[13]20MAFT (vulvovaginal)6 moMixed-indication sexual-function cohort (18 menstruating, two perimenopausal). The authors reported improved sexual-function responses, but questionnaire totals were not on the validated 36-point FSFI scale; histology came from one additional patient.
Mantovani 2022[17]12MFAT (SEFFIGYN™)5 moAll symptoms significantly improved (p = 0.001–0.008); all patients resumed sexual life

The Moccia 2023 SR of injection treatments for VVA found that microfat, nanofat and PRP led to significant improvement on VHI and FSDS-R, but MFAT alone did not reach significance on validated questionnaires in the studies assessed.[18]

Positioning vs standard GSM therapies​

TherapyMechanismDurabilityKey advantageKey limitation
Low-dose vaginal estrogenRestores ER signalingContinuous useMost robust evidence of the GSM therapies; AUA/SUFU/AUGS 2025 Strong Recommendation (Grade C)[40]Continuous therapy; counseled cautiously in HR+ breast cancer survivors on AIs
Vaginal DHEA (prasterone)Local androgen → estrogen conversionContinuousFDA-approved for moderate-to-severe dyspareunia due to menopause[55]; the GSM guideline supports offering it for dryness and/or dyspareunia[40]Daily application
OspemifeneOral SERM with vaginal estrogenic effectContinuousOral; non-vaginal routeLimited cancer-safety data
CO₂ / Er:YAG laserMicroablation → collagen remodelingMultiple sessionsNon-hormonal, office-basedAUA/SUFU/AUGS 2025 says evidence does not support CO₂ or Er:YAG laser for GSM symptoms ; it permits consideration of CO₂ laser only as experimental for patients who cannot use or prefer alternatives to FDA-approved treatment . FDA has not cleared GSM indications.[40]
Microfat / nanofat / MFATVolume replacement and hypothesized trophic effectsOne MFAT case series followed 35 women for 36 mo[16]Autologous materialNo controlled GSM efficacy trial; MFAT questionnaire benefit was not significant in the 2023 injection-treatment review; requires liposuction[18]

The 2025 AUA/SUFU/AUGS guideline identifies low-dose vaginal estrogen as the hormonal therapy with the strongest evidence. It does not rank the hormonal therapies against one another or require a stepwise sequence; the choice follows shared decision-making.[40] Fat grafting is not yet incorporated into any GSM guideline.

The estrogen paradox in postmenopausal fat grafting​

Treating GSM with fat grafting means transferring autologous adipose between two hypoestrogenic compartments, and the preclinical signals point in opposing directions:

  • Low E2 paradoxically favors volumetric retention. In ovariectomized mice, fat-graft retention was 79% versus 35% in controls, driven by enhanced early macrophage infiltration and adipocyte hypertrophy.[41] In a preclinical mouse-grafting experiment using fat from one young and one elderly woman, the elderly donor sample had higher retention under low-estrogen conditions.[42]
  • But E2 supports ADSC regenerative function. Estradiol-treated ADSCs increased VEGF output and graft survival (77% versus 56%) in nude-mouse models.[43]
  • Postmenopausal ASCs are transcriptomically distinct. RNA-seq shows approximately 2,299 differentially expressed genes versus premenopausal ASCs, with altered immunoregulation (M1 polarization).[44]
  • Estrogen effects are donor-depot-specific (femoral versus abdominal) and more important at donor than recipient site.[45]

Human vulvovaginal graft retention and any relationship between estrogen status and the 9–12-month symptom course in the uncontrolled MFAT series remain undetermined.[16][42]

GSM in breast cancer survivors — the highest-unmet-need population​

GSM affects an estimated 60% of postmenopausal breast cancer survivors and is typically worsened by aromatase-inhibitor (AI) estrogen depletion.[54] The 2024 Lancet review summarizes non-hormonal therapies as first-line for breast cancer survivors and local estrogen for persistent symptoms after discussion with the treating oncologist.[46] The AUA/SUFU/AUGS 2025 guideline states that clinicians may recommend local low-dose vaginal estrogen for patients with a personal history of breast cancer within multidisciplinary shared decision-making .[40] Fat grafting is mechanistically attractive (autologous, non-hormonal) but two caveats apply:

  • No published study has specifically evaluated fat grafting for GSM in breast cancer survivors.
  • In Lai 2023, increased vaginal-tissue ER staining was measured in one separate patient who underwent later vaginoplasty, not in the 20-person clinical cohort.[13]
  • An uncontrolled PRP pilot for GSM treated 20 breast cancer survivors (17 HR-positive, of whom 11/17 [65%] were on AIs); no serious adverse events were reported and symptom measures improved through 6 mo.[47]

FDA regulatory positioning​

  • Autologous fat transfer. FDA guidance says rinsing, cleansing, sizing, shaping, or centrifugation solely to remove debris may preserve the same-surgical-procedure exception; cell isolation generally does not. If the exception does not apply, assess all four 21 CFR 1271.10(a) criteria: minimal manipulation, homologous use, whether the adipose product is combined with another article during manufacture (including PRP if physically mixed), and the systemic-effect/cell-activity criterion; claimed regenerative GSM or VLS use needs product-specific review.[48][49][50]
  • Enzymatically isolated SVF (collagenase digestion): classified by the FDA as more than minimally manipulated; regulated as a 351 HCT/P biological product.[48]
  • Mechanically isolated SVF or nanofat. FDA guidance states that mechanically disrupting adipose tissue to isolate SVF is generally more than minimal manipulation and usually does not qualify for the same-surgical-procedure exception. Nanofat requires assessment of its actual processing and intended use.[49][50]

Vulvar lichen sclerosus (VLS) — refractory to topical steroids​

Rationale​

VLS is a chronic relapsing inflammatory dermatosis with progressive atrophy, stromal hyalinization, decreased microvessel density, and architectural distortion (clitoral burying, labial fusion, introital stenosis, dyspareunia). Topical corticosteroid ointment is first-line: ACOG 2020 recommends a medium- or high-potency ointment such as clobetasol propionate 0.05% or mometasone furoate 0.1% (Level A), and the 2026 German S3 guideline names ultrapotent or potent corticosteroids with emollients as standard therapy.[25][26] In a cohort of 327 girls and women treated with topical corticosteroids, symptoms improved in 244 of the 255 with a recorded response (96%), although 76 (30%) had only a partial response;[57] scarring, atrophy, and sexual dysfunction can persist.[25][26][27] Experimental ADSC data suggest anti-inflammatory, vascular, and antifibrotic mechanisms, but clinical disease modification in VLS is unproven. Fat grafting remains an investigational adjunct; topical calcineurin inhibitors are the guideline's second choice when corticosteroids are inadequate or unsuitable.[26][28] For the disease context, see Lichen Sclerosus.

Three-pillar mechanism in VLS​

PillarADSC effectHistologic confirmation in VLS
Anti-fibroticDownregulation of Col-1, Col-3, α-SMA, IL-17, p38/MAPK; mechanical rigottomy disrupts fibrotic bands[28]Reduced stromal hyalinization at 12 mo (Lichen-SVF, p = 0.0036)[19]
Immunomodulatory↓ IL-6, TNF-α, STAT3/STAT6; ↑ IL-10; M1 → M2 macrophage polarization[28]Reduced CD3+ T-cell infiltration (Lichen-SVF, p = 0.0068); decrease in all inflammatory cell types on biopsy in the only RCT[15][19]
Pro-angiogenic↑ VEGF, HGF, bFGF; ADSC → pericyte differentiation[28]Increased microvascular density at 12 mo (Lichen-SVF, p = 0.0121)[19]

Why combine PRP with fat grafting?​

Three of the five listed studies evaluated PRP plus adipose-based therapy (132 enrolled across those studies, including comparator arms and Tedesco's mixed-sex cohort); 189 participants were initially enrolled across all five, and 18 of 21 Lichen-SVF participants completed 12-month follow-up.[19][20][15][30][34][35] Platelet growth factors (PDGF, TGF-β1, VEGF, EGF, IGF-1, FGF) provide a rationale for study.[19][20][15][30][34][35] These clinical reports do not isolate PRP's contribution to vulvar outcomes.[19][20][15][30][34][35] Preclinical data support a true synergy:

  • Amplified angiogenic output. MSCs cultured with PRP secrete > 4× more VEGF plus increased uPA and ET-1 versus MSCs alone.[36]
  • Enhanced ADSC proliferation and pluripotency. Platelet-rich-fibrin extract upregulates NANOG, SOX2, and proliferation markers in ADSCs.[37]
  • Platelet to ADSC mitochondrial transfer restores mitochondrial function, reduces ROS, and improves graft survival under oxidative stress, directly relevant to the chronically inflamed VLS bed.[38]
  • i-PRF directly attenuates VLS fibrosis via TGF-β / SMAD3 pathway inhibition (↓ fibronectin, Col-1) and NF-κB inhibition (↓ IL-17, IFN-γ), with concurrent ↑ CD31 / VEGF expression, providing a stand-alone fibroreductive mechanism that complements the ADSC effects above.[39]

Combination therapy is most beneficial in early-stage disease (Tedesco); in late-stage or heavily hyalinized disease the regenerative ceiling appears lower regardless of PRP enrichment.[20]

Selected clinical evidence​

A prospective uncontrolled cohort of 33 women reported symptom and sexual-function improvement at a mean 12.9 months.[51] In a later observational reevaluation of 71 previously treated women, 88.7% were satisfied or very satisfied, with follow-up reaching 11 years.[51][52]

StudyYearDesignnInterventionFollow-upKey outcomes
Boero[29]2015Prospective cohort36Microfat (Coleman)NR94% improved trophism; 75% improved introital caliber; 50% reduced clitoral burying; 95% stopped routine TCS; DLQI / FSFI significantly improved (p < 0.001)
Tedesco[20]2020RCT 1:140 (mixed-sex genital LS cohort)AD-SVF vs AD-SVF + PRP6 moBoth arms improved DLQI; combination superior in early-stage; combination discouraged in late-stage disease
Gutierrez-Ontalvilla[15]2022RCT (pilot)20 clobetasol nonresponders randomized (19 assessed)Nanofat + PRP ×2 (q3mo) vs topical clobetasol12 moSignificant improvement in itching, pain, burning, dyspareunia, erosions, fissures, stenosis, leukoderma; biopsy ↓ inflammatory cells; no improvement in skin elasticity; only RCT vs TCS
Casabona[30]2023Retrospective cohort72PRP + fat grafting; median four procedures (IQR 3–8)3 mo after final procedureSkindex-29 −31.8; FSFI +7.6; DLQI −9; CSS −24; IGA −4 (within-patient changes, all p < 0.001); largest listed cohort but short post-treatment assessment
Gutierrez-Ontalvilla (Lichen-SVF)[19]2025Prospective open-label21 enrolled; 18 completedNanofat 40 mL + mechanically isolated SVF 2–3 mL, single treatment12 moCSS Symptoms 20.1 → 4.7 (p = 0.003); CSS Signs 5.8 → 2.0 (p = 0.001); 5D Itch 6.8 → 2.4 (p = 0.014); Skindex-29 42.9 → 24.8 (p = 0.031); FSFI non-significant; biopsy showed reduced hyalinization and T-cell infiltration and increased microvascular density

Comparison with other approaches for refractory VLS​

ApproachInvasivenessLargest nKey advantageKey limitation
Fat grafting ± PRP / SVFMinimal72Targets inflammation and fibrosis directly; repeatable; favorable safetyDoes not improve skin elasticity; limited long-term data; less effective late-stage[15][20]
PRP monotherapyMinimal50Reduces TCS need ~42%; improves elasticity / colorNo volume restoration; limited durability[31]
Vulvar laser (Nd:YAG/Er:YAG; fractional CO₂)Minimal66 analyzed in the 2024 dual-laser RCT; 245 randomized in the 2026 CO₂ RCTThe dual-laser trial favored laser on a 6-mo clinical LS score; the open-label CO₂ trial favored laser on 3-mo BIP symptom change versus clobetasolFour dual-laser or three CO₂ sessions studied; longer-term inflammatory control, scarring and cancer outcomes remain unproved[32][56]
Perineoplasty / de-adhesionModerateVariableAddresses introital stenosis, labial adhesionsVariable durability
aOAP flap (O'Dey)High61 surgically treated; 53 bilateral aOAP flapsTissue replacement; dyspareunia decreased at 1 year in this retrospective cohortMajor surgery; LS tissue may raise minor postoperative-complication risk[33]

See also Vulvar Reconstruction and the aOAP Flap atlas page.

Positioning and unanswered questions​

  • Not yet in formal guidelines. ACOG 2020 (medium- or high-potency) and the 2026 German S3 guideline (ultrapotent or potent) keep TCS first-line and topical calcineurin inhibitors second-line; fat grafting remains investigational for refractory disease.[25][26]
  • Complementary, not curative. The Lichen-SVF protocol maintained topical corticosteroids. Before a VLS procedure, confirm adequate topical treatment, assess worsening symptoms for infection, contact allergy or malignancy, and biopsy suspicious lesions; agree on topical treatment before and after surgery and continued surveillance.[19][26]
  • Therapeutic window. Combination SVF plus PRP was less effective in late-stage disease (Tedesco) and elasticity did not improve in the only RCT (Gutierrez-Ontalvilla 2022).[15][20]
  • Malignancy surveillance unchanged. VLS carries a 2–5% estimated vulvar SCC risk; one of 72 women in the Casabona series developed vulvar SCC during follow-up, and the effect of grafting on cancer risk remains unknown.[25][30] Continue surveillance and biopsy suspicious lesions regardless of regenerative therapy.[25]
  • Open questions. Standardized protocol (microfat versus nanofat versus SVF; volumes; sessions); durability beyond 12 mo; head-to-head trials versus PRP monotherapy and versus laser.

Duration of effect — a defining advantage​

Uncontrolled fat-grafting series reported outcomes through 18 and 36 months, respectively; comparative durability versus other injections is undetermined.[1][16]

  • 18 mo. Stable in all patients with further FSD improvement between 12 and 18 mo (Menkes 2021).[1]
  • 36 mo. In an uncontrolled 35-woman MFAT series, 30/35 (85%) were asymptomatic at 12 months and 3/35 reported mild symptoms at 24–36 months; one nonresponder with structural scarring received a second treatment at 14 months.[16] The 35-woman MFAT series reported clinical follow-up through 36 mo;[16] 36-mo biopsies showing tissue changes consistent with regeneration were reported in a separate three-woman MFAT series.[3]

Comparison with other vaginal-injection treatments for GSM​

AgentMechanismVolume effectRegenerative effectDurationSessions
Microfat + nanofatVolume plus hypothesized trophic effectsYes (microfat)Clinical regenerative effect unproven18 mo in one uncontrolled combination series; 36 mo in a separate MFAT seriesUsually single[1][16][18]
Cross-linked HAVolume + mild tissue stimulationYesModerate (collagen mRNA upregulation)Not established (8-wk assessment)Retreatment undetermined[18][53]
PRPGrowth-factor-mediated regenerationNoModerateVariableMultiple[18]
MFAT (Lipogems®)Volume plus hypothesized trophic effectsModerateTissue changes in a three-person biopsy series; clinical disease modification unprovenUp to 36 mo in uncontrolled follow-upUsually one; repeat treatment reported[16][3]
CollagenVolume + analgesicMildMildNot established (3 mo after final injection assessed)Five sessions studied[21]

Complications and safety​

Small published GSM and VLS series reported few immediate procedure-related adverse events.[1][13][19][5]

Minor complications (common)​

  • Ecchymosis at donor and recipient sites
  • Transient tenderness and swelling
  • Mild pain at injection sites[22]

Potential serious complications (rare but consequential)​

  • Fat embolism (most serious). Wang 2020 case report of severe pulmonary fat embolism after vaginal fat grafting, with fat presumably injected directly into perivaginal vessels. It is the most serious safety concern; anatomical knowledge and careful injection technique are important.[5]
  • GRAFT registry (7,052 fat-grafting procedures at breast, face, buttock, and other sites): among 4,390 procedures with at least one follow-up visit, 220 had a recorded complication (5.01%); reported types included palpable mass, infection, and oil cyst, with rates varying by site.[23]
  • Vascular embolism is the principal serious risk of vaginal-wall injection and must be actively prevented.[24]
  • Tonnard's cutaneous nanofat series reported no infections, fat cysts, granulomas, or other unwanted effects.[9] Menkes reported no major adverse effects in 50 microfat/nanofat recipients, while Lai's separate MAFT cohort reported one palpable nodule among 20 women.[1][13]

Advantages and limitations​

Advantages

  • Autologous material; no allergic or foreign-body reactions.
  • Dual mechanism: volume restoration (microfat) and tissue regeneration (nanofat).
  • Uncontrolled GSM/MFAT series report symptom improvement through 18–36 months after treatment; comparative durability is unknown, and the largest VLS cohort used a median four PRP–fat procedures.[1][16][30]
  • Small uncontrolled studies report tissue-marker changes after MFAT or nanofat-based treatment; clinical disease reversal attributable to grafting remains unproven.[3][13][19]
  • Applicable to both GSM and refractory VLS.

Limitations

  • Requires a donor-site procedure (liposuction), with additional surgical complexity and morbidity.
  • Not suitable for patients with very low body fat.
  • Evidence base is observational studies and small case series (Level III–IV); no large RCTs specifically for GSM.
  • Variable fat-graft survival; unpredictable resorption.
  • Risk of pulmonary fat embolism. A severe case followed combined vaginal and breast fat grafting; its incidence after vaginal fat grafting is unknown.[5]
  • Lack of standardized protocols. Volumes, processing methods, and injection sites vary across studies.
  • ACOG 2020 and FIGO 2025 classify cosmetic genital procedures as not medically indicated.[4][6] The GSM or VLS-refractory therapeutic context is distinct, but counseling must clearly distinguish.[4]

Emerging directions​

  • SVF-enriched nanofat (Lichen-SVF protocol) for VLS with histologically confirmed anti-inflammatory and regenerative effects.[19]
  • Nanofat plus PRP combinations for early-stage VLS.[15][20]
  • Proteomic and lipidomic profiling of nanofat to identify specific bioactive mediators responsible for regenerative effects.[11][12]
  • ADSC-enriched nanofat with higher pluripotent (MUSE) stem-cell content.[10]

Key takeaways​

  • Small uncontrolled studies report symptom and tissue-marker improvements after fat grafting for GSM or VLS.[1][3][19][40]
  • In a 35-patient MFAT series, symptom improvement after one injection was reported through 36 mo; a separate three-patient series at 36 mo showed epithelial and subcutaneous regeneration and vasculature hyperplasia on biopsy, plus restored acidic pH and lactobacilli on vaginal sampling.[16][3]
  • The strongest evidence is for GSM and VLS-refractory disease rather than cosmetic enhancement in healthy women.
  • GSM evidence remains observational; VLS has small randomized and uncontrolled studies. Severe pulmonary fat embolism has been reported after combined vaginal and breast grafting, but its procedure-specific frequency is unknown.[5][15][20][18]
  • Larger RCTs are needed to standardize protocols and confirm long-term safety.

Postoperative management​

  • Activity restriction. Avoid intercourse, tampon use, and strenuous exercise for 2–4 weeks; protect donor site per general lipofilling protocol.
  • Donor-site care. Compression at donor site; avoid pressure on recipient site so as not to compress the graft.
  • Wound care. Ice 48–72 h; loose-fitting clothing; antibiotic ointment to donor incisions.
  • Follow-up. 1 week, 6 weeks, 6 months, 12 months, with VHI / FSFI / FSD as relevant; some series have extended to 18–36 months.
  • Counseling on durability. Counsel that regenerative effects may continue to emerge between 6 and 18 months.

See Also​

References​

1. Menkes S, SidAhmed-Mezi M, Meningaud JP, et al. Microfat and nanofat grafting in genital rejuvenation. Aesthet Surg J. 2021;41(9):1060–1067. doi:10.1093/asj/sjaa118

2. Ding P, Lu E, Li G, et al. Research progress on preparation, mechanism, and clinical application of nanofat. J Burn Care Res. 2022;43(5):1140–1144. doi:10.1093/jbcr/irab250

3. Casarotti GA, Chiodera P, Tremolada C. Menopause: new frontiers in the treatment of urogenital atrophy. Eur Rev Med Pharmacol Sci. 2018;22(2):567–574. doi:10.26355/eurrev_201801_14211

4. Committee on Gynecologic Practice, American College of Obstetricians and Gynecologists. Elective female genital cosmetic surgery: ACOG Committee Opinion No. 795. Obstet Gynecol. 2020;135(1):e36–e42. doi:10.1097/AOG.0000000000003616

5. Wang C, Wang X, Huang J, Yu N, Long X. Severe fat embolism after autologous fat grafting in vaginal tightening and breast augmentation surgery. J Int Med Res. 2020;48(8):300060520949109. doi:10.1177/0300060520949109

6. Capito L, Antsaklis A, Gupte S. FIGO Statement: cosmetic genital surgery. Int J Gynaecol Obstet. 2025;170(1):11–14. doi:10.1002/ijgo.70203

7. Kamat P, Frueh FS, McLuckie M, et al. Adipose tissue and the vascularization of biomaterials: stem cells, microvascular fragments and nanofat — a review. Cytotherapy. 2020;22(8):400–411. doi:10.1016/j.jcyt.2020.03.433

8. Yang Z, Jin S, He Y, et al. Comparison of microfat, nanofat, and extracellular matrix/stromal vascular fraction gel for skin rejuvenation: basic research and clinical applications. Aesthet Surg J. 2021;41(11):NP1557–NP1570. doi:10.1093/asj/sjab033

9. Tonnard P, Verpaele A, Peeters G, et al. Nanofat grafting: basic research and clinical applications. Plast Reconstr Surg. 2013;132(4):1017–1026. doi:10.1097/PRS.0b013e31829fe1b0

10. Quintero Sierra LA, Biswas R, Conti A, et al. Highly pluripotent adipose-derived stem cell-enriched nanofat: a novel translational system in stem cell therapy. Cell Transplant. 2023;32:9636897231175968. doi:10.1177/09636897231175968

11. Sanchez-Macedo N, McLuckie M, Grünherz L, Lindenblatt N. Protein profiling of mechanically processed lipoaspirates: discovering wound healing and antifibrotic biomarkers in nanofat. Plast Reconstr Surg. 2022;150(2):341e–354e. doi:10.1097/PRS.0000000000009345

12. Grünherz L, Kollarik S, Sanchez-Macedo N, McLuckie M, Lindenblatt N. Lipidomic analysis of microfat and nanofat reveals different lipid mediator compositions. Plast Reconstr Surg. 2024;154(5):895e–905e. doi:10.1097/PRS.0000000000011335

13. Lai YW, Wu SH, Chou PR, et al. Autologous fat grafting in female genital area improves sexual function by increasing collagenesis, angiogenesis, and estrogen receptors. Aesthet Surg J. 2023;43(8):872–884. doi:10.1093/asj/sjad040

14. Strong AL, Cederna PS, Rubin JP, Coleman SR, Levi B. The current state of fat grafting: a review of harvesting, processing, and injection techniques. Plast Reconstr Surg. 2015;136(4):897–912. doi:10.1097/PRS.0000000000001590

15. Gutierrez-Ontalvilla P, Giner F, Vidal L, Iborra M. The effect of lipofilling and platelet-rich plasma on patients with moderate-severe vulvar lichen sclerosus who were non-responders to topical clobetasol propionate: a randomized pilot study. Aesthet Plast Surg. 2022;46(5):2469–2479. doi:10.1007/s00266-021-02718-1

16. Casarotti G, Tremolada C. A new treatment of genito-urinary post-menopausal atrophy with autologous micro-fragmented fat tissue: a thirty-six months follow-up case series. Eur Rev Med Pharmacol Sci. 2020;24(13):7420–7426. doi:10.26355/eurrev_202007_21910

17. Mantovani M, Gennai A, Russo PR. A new approach to regenerative medicine in gynecology. Int J Gynaecol Obstet. 2022;157(3):536–543. doi:10.1002/ijgo.13906

18. Moccia F, Pentangelo P, Ceccaroni A, et al. Injection treatments for vulvovaginal atrophy of menopause: a systematic review. Aesthet Plast Surg. 2023;47(6):2788–2799. doi:10.1007/s00266-023-03550-5

19. Gutierrez-Ontalvilla P, Gomez Rojas A, Iborra Colomino M, et al. Clinical and histopathological investigation of stromal vascular fraction and nanofat in vulvar lichen sclerosus. Aesthet Surg J. 2025;sjaf148. doi:10.1093/asj/sjaf148

20. Tedesco M, Bellei B, Garelli V, et al. Adipose tissue stromal vascular fraction and adipose tissue stromal vascular fraction plus platelet-rich plasma grafting: new regenerative perspectives in genital lichen sclerosus. Dermatol Ther. 2020;33(6):e14277. doi:10.1111/dth.14277

21. Borobia Pérez AI, Estévez Espejo JJ, Jiménez-González M, García López RD. Vulvovaginal collagen injection as a regenerative strategy in genitourinary syndrome of menopause: results of a pilot study. J Clin Med. 2026;15(4):1408. doi:10.3390/jcm15041408

22. Cihantimur B, Aglamis O, Ozsular Y. 360 genital fat transfer. Aesthet Plast Surg. 2021;45(6):2996–3002. doi:10.1007/s00266-021-02488-w

23. Kaur S, Rubin JP, Gusenoff J, et al. The General Registry of Autologous Fat Transfer: concept, design, and analysis of fat grafting complications. Plast Reconstr Surg. 2022;149(6):1118e–1129e. doi:10.1097/PRS.0000000000009162

24. Zheng Z, Yin J, Cheng B, Huang W. Materials selection for the injection into vaginal wall for treatment of vaginal atrophy. Aesthet Plast Surg. 2021;45(3):1231–1241. doi:10.1007/s00266-020-02054-w

25. Committee on Practice Bulletins–Gynecology. Diagnosis and management of vulvar skin disorders: ACOG Practice Bulletin No. 224. Obstet Gynecol. 2020;136(1):e1–e14. doi:10.1097/AOG.0000000000003944

26. Kirtschig G, Woelber L, Günthert A, et al. Evidence- and consensus-based guideline on lichen sclerosus. J Dtsch Dermatol Ges. 2026;24(4):566–584. doi:10.1111/ddg.70000

27. Brodrick B, Belkin ZR, Goldstein AT. Influence of treatments on prognosis for vulvar lichen sclerosus: facts and controversies. Clin Dermatol. 2013;31(6):780–786. doi:10.1016/j.clindermatol.2013.05.017

28. van der Sluis N, Scheers ECAH, Krenning G, et al. Autologous lipoaspirate as a new treatment of vulvar lichen sclerosus: a review of the literature. Exp Dermatol. 2022;31(5):689–699. doi:10.1111/exd.14561

29. Boero V, Brambilla M, Sipio E, et al. Vulvar lichen sclerosus: a new regenerative approach through fat grafting. Gynecol Oncol. 2015;139(3):471–475. doi:10.1016/j.ygyno.2015.10.014

30. Casabona F, Gasparini G, Cozzani E, et al. Improvement in quality of life and sexual function in patients affected by vulvar lichen sclerosus treated with combined autologous platelet-rich plasma and fat grafting. Eur J Dermatol. 2023;33(3):249–254. doi:10.1684/ejd.2023.4480

31. Boero V, Cetera GE, Caia C, et al. Is there a role for platelet-rich plasma injection in vulvar lichen sclerosus? A self-controlled pilot study. Arch Gynecol Obstet. 2024;309(6):2719–2726. doi:10.1007/s00404-024-07424-2

32. Zivanovic I, Gamper M, Fesslmeier D, et al. Nd:YAG/Er:YAG dual laser compared with topical steroid to treat vulvar lichen sclerosus: a randomised controlled trial. BJOG. 2024;131(6):740–749. doi:10.1111/1471-0528.17737

33. O'Dey DM, Rosendahl M, Mordehay D, Kameh Khosh M. Anterior obturator artery perforator (aOAP) flap: a last-resort treatment option for sexual dysfunction in lichen sclerosus et atrophicus. J Plast Reconstr Aesthet Surg. 2024;95:331–339. doi:10.1016/j.bjps.2024.05.046

34. Tobita M, Tajima S, Mizuno H. Adipose tissue-derived mesenchymal stem cells and platelet-rich plasma: stem cell transplantation methods that enhance stemness. Stem Cell Res Ther. 2015;6:215. doi:10.1186/s13287-015-0217-8

35. Tatsis D, Vasalou V, Kotidis E, et al. The combined use of platelet-rich plasma and adipose-derived mesenchymal stem cells promotes healing: a review of experimental models and future perspectives. Biomolecules. 2021;11(10):1403. doi:10.3390/biom11101403

36. Myung H, Jang H, Myung JK, et al. Platelet-rich plasma improves the therapeutic efficacy of mesenchymal stem cells by enhancing their secretion of angiogenic factors in a combined radiation and wound injury model. Exp Dermatol. 2020;29(2):158–167. doi:10.1111/exd.14042

37. Wachtel N, Weber L, Moellhoff N, et al. Platelet-rich fibrin mediates beneficial effects on adipose-derived stem cells via increased levels of key cytokines. Wound Repair Regen. 2025;33(3):e70040. doi:10.1111/wrr.70040

38. Ke C, Liu K, Chen W, et al. Platelets facilitate fat grafting by mitochondrial transfer and reducing oxidative stress in adipose-derived stem cells. Stem Cells Transl Med. 2025;14(11):szaf059. doi:10.1093/stcltm/szaf059

39. Sun SH, Fan HH, Wang XW, Bing BD, Hu YJ. Platelet-rich fibrin attenuates inflammation and fibrosis in vulvar lichen sclerosus via the TGF-β/SMAD3 pathway. Arch Dermatol Res. 2025;317(1):360. doi:10.1007/s00403-025-03811-0

40. Kaufman MR, Ackerman AL, Amin KA, et al. The AUA/SUFU/AUGS guideline on genitourinary syndrome of menopause. J Urol. 2025;214(3):242–250. doi:10.1097/JU.0000000000004589

41. Mok H, Feng J, Hu W, et al. Decreased serum estrogen improves fat graft retention by enhancing early macrophage infiltration and inducing adipocyte hypertrophy. Biochem Biophys Res Commun. 2018;501(1):266–272. doi:10.1016/j.bbrc.2018.04.232

42. Xie W, Li F, Zhang Y, et al. Elderly women have a higher survival rate of grafted donor fat than do young women under the influence of low-estrogen conditions. Aesthet Plast Surg. 2024;48(15):2879–2886. doi:10.1007/s00266-024-04095-x

43. Luo S, Hao L, Li X, et al. Adipose tissue-derived stem cells treated with estradiol enhance survival of autologous fat transplants. Tohoku J Exp Med. 2013;231(2):101–110. doi:10.1620/tjem.231.101

44. Xie Y, Fang B, Liu W, et al. Transcriptome differences in adipose stromal cells derived from pre- and postmenopausal women. Stem Cell Res Ther. 2020;11(1):92. doi:10.1186/s13287-020-01613-x

45. Bills JD, Derderian C, Barker J, et al. The role of estrogen in the modulation of autologous fat graft outcomes. Plast Reconstr Surg. 2015;135(1):103e–113e. doi:10.1097/PRS.0000000000000792

46. Hickey M, Basu P, Sassarini J, et al. Managing menopause after cancer. Lancet. 2024;403(10430):984–996. doi:10.1016/S0140-6736(23)02802-7

47. Chen AH, Trabuco EC, Chumsri S, et al. Platelet-rich plasma for genitourinary syndrome of menopause in breast cancer survivors. Obstet Gynecol. 2025;Online ahead of print. doi:10.1097/AOG.0000000000006081

48. Rohrich RJ, Wan D. Making sense of stem cells and fat grafting in plastic surgery: the hype, evidence, and evolving U.S. Food and Drug Administration regulations. Plast Reconstr Surg. 2019;143(2):417e–424e. doi:10.1097/PRS.0000000000005207

49. U.S. Food and Drug Administration. "Same Surgical Procedure Exception under 21 CFR 1271.15(b): Questions and Answers Regarding the Scope of the Exception." Guidance for Industry. 2017. https://www.fda.gov/media/89920/download

50. U.S. Food and Drug Administration. "Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use." Guidance for Industry and FDA Staff. 2017. https://www.fda.gov/media/109176/download

51. Almadori A, Hansen E, Boyle D, et al. "Fat grafting improves fibrosis and scarring in vulvar lichen sclerosus: results from a prospective cohort study." J Low Genit Tract Dis. 2020;24(3):305–310. doi:10.1097/LGT.0000000000000520

52. Boero V, Brambilla M, Di Loreto E, et al. "Fat grafting in vulvar lichen sclerosus: long term follow-up." J Low Genit Tract Dis. 2023;27(4):365–372. doi:10.1097/LGT.0000000000000766

53. Berreni N, Salerno J, Chevalier T, Alonso S, Mares P. "Evaluation of the effect of multipoint intra-mucosal vaginal injection of a specific cross-linked hyaluronic acid for vulvovaginal atrophy: a prospective bi-centric pilot study." BMC Womens Health. 2021;21:322. doi:10.1186/s12905-021-01435-w

54. Moreno AC, Sikka SK, Thacker HL. "Genitourinary syndrome of menopause in breast cancer survivors: Treatments are available." Cleve Clin J Med. 2018;85(10):760–766. doi:10.3949/ccjm.85a.17108

55. U.S. National Library of Medicine. INTRAROSA (prasterone) vaginal insert, prescribing information, revised January 2026. DailyMed label.

56. Hecken JM, Shoham I, Tempfer CB, Rezniczek GA. "Laser Treatment Compared with Topical Clobetasol for Lichen Sclerosus: A Randomized Controlled Trial." Obstet Gynecol. 2026;148(4):451–461. doi:10.1097/AOG.0000000000006326

57. Cooper SM, Gao XH, Powell JJ, Wojnarowska F. Does treatment of vulvar lichen sclerosus influence its prognosis? Arch Dermatol. 2004;140(6):702–706. doi:10.1001/archderm.140.6.702